ArticleAmerican journal of cancer research2025
Impact of clinicopathological features of meibomian gland adenocarcinoma on the outcomes of surgical resection combined with eyelid reconstruction.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the clinical and pathological characteristics of meibomian gland carcinoma (MGC) and their impact on the outcomes of surgical resection combined with eyelid defect reconstruction. A retrospective study was conducted on 128 patients diagnosed with MGC between December 2020 and January 2022. Demographic, clinical, pathological, surgical, and postoperative follow-up data were collected from the medical records. Patients were divided into two groups based on their total aesthetic outcome score: the satisfied group (score ≥27, n=87) and the dissatisfied group (score <27, n=41). Additionally, patients were categorized into recurrence (n=29) and non-recurrence groups (n=99) based on postoperative recurrence status. Results showed that age (OR=1.080, 95% CI: 1.015~1.149, P=0.015), tumor size (OR=1.625, 95% CI: 0.681~0.887, P<0.001), and tumor stage (OR1=0.007, 95% CI: 0.001~0.070; OR2=0.019, 95% CI: 0.003~0.145, P<0.001) significantly influenced aesthetic outcomes following surgical resection combined with eyelid defect reconstruction. Recurrence analysis indicated that tumor size (HR=1.224, 95% CI: 1.091~1.374, P<0.001) and stage (HR1=0.008, 95% CI: 0.001~0.084; HR2=0.051, 95% CI: 0.011~0.242, P<0.001) were significant factors affecting the recurrence. Receiver operating characteristic (ROC) curve analysis demonstrated that the combined prediction of clinical and pathological features had the highest efficacy in predicting aesthetic outcomes and tumor recurrence following surgical resection and reconstruction (aesthetic outcome: Z=5.544, 3.110, 4.527; recurrence: Z=3.319, 2.986; all P<0.05). The Kaplan-Meier survival curve revealed significant differences in disease-free survival rates across different stages of tumors (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.